Mercer Island, WA – According to filings with the U.S. Securities and Exchange Commission, AltPep is raising $23,149,994.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Valerie Daggett played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AltPep

AltPep Corporation is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world’s most intractable diseases: amyloid diseases. We are currently focusing on CNS disorders, in particular Alzheimer’s Disease (AD). We target and seek to neutralize the early toxic oligomers behind these amyloid diseases, which in the case of AD are due to aggregation of the Amyloid-beta peptide (Abeta). AltPep spun out from the Daggett Research Group lab at the University of Washington, and AltPep’s technology is based on decades of research and discoveries from the lab, culminating in technology that targets a fundamental toxic protein structure formed during amyloidogenesis.

To learn more about AltPep, visit http://www.altpep.com/

Contact:
Valerie Daggett, Chief Executive Officer
425-269-2862
https://www.linkedin.com/in/valerie-daggett-83690b98/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved